Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12503801 | 0.89 | LMNA (0.43) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL4113357 | 0.81 | ALDH1A1 (0.40) | LMNAALDH1A1 | |
| SCHEMBL519006 | 0.75 | LMNA (0.45) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL4122365 | 0.73 | LMNA (0.43) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL105238 | 0.73 | — | — | |
| SCHEMBL4969707 | 0.71 | LMNA (0.41) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL19543140 | 0.71 | LMNA (0.41) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL20438511 | 0.71 | LMNA (0.41) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL20438365 | 0.71 | LMNA (0.41) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL9299279 | 0.71 | MEN1 (0.46) | LMNAALDH1A1KDM4CKDM4APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093468-A1 | Peptide Deformylase Inhibitors | ARPIDA A/S (DK) | 2009-04-09 | — | — | US | disclosed |
| US-20070066672-A1 | Benzimidazole derivatives and use thereof as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| EP-1732907-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Arpida A/S (DK) | 2006-12-20 | — | — | EP | disclosed |
| EP-1677785-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS PEPTIDE DEFORMYLASE INHIBITORS | Arpida A/S (DK) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005092872-A1 | PEPTIDE DEFORMYLASE INHIBITORS | ARPIDA A/S (DK) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005037272-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS PEPTIDE DEFORMYLASE INHIBITORS | ARPIDA A/S (DK) | 2005-04-28 | — | — | WO | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066672-A1 | Benzimidazole derivatives and use thereof as peptide deformylase inhibitors | PDF, MRPL21, PEPD | LMNA 1563/4885ALDH1A1 1380/4885KDM4C 4175/4885 |
| US-20090093468-A1 | Peptide Deformylase Inhibitors | PDF, PEPD, MRPL21 | LMNA 2707/4885ALDH1A1 2279/4885KDM4C 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.